G. Matusow

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

E. Yoshida, G. de la Rosa, E. Lawitz, 2016, Hepatology.

Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device

C. Bernaards, K. Beavers, E. Lawitz, 2011, Patient preference and adherence.

LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2

E. Yoshida, E. Lawitz, M. Peeters, 2015 .